Browsing Tag

aTyrpharma

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or…

Jason Junior Jan 19, 2023

SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced…

Health

aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium

Jason Junior Oct 4, 2022

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced…

Health

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jason Junior May 14, 2022

SAN DIEGO, May 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today…

Health

aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of…

Jason Junior Apr 14, 2022

SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced…